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INTRODUCTION
The Philadelphia chromosome (Ph) is found in 20% to
30% of adults and 3% to 5% of children with acute lym-
phoblastic leukemia (ALL) [1-4]. In 1 study of 307 children
with relapsed ALL, the percentage of Ph+ cases was almost
10% [5]. Approximately 41% to 86% of Ph+ patients have
associated chromosomal abnormalities, most commonly
anomalies of chromosome 9p, monosomy 7, or hyper-
diploidy [6]. The lymphoblasts are usually L1 or L2 by mor-
phology and pre-B by immunophenotype with CD10,
CD19, and CD34 positivity, and they often express myeloid
markers such as CD13 and CD33 [4,7,8]. There are data to
suggest that Ph+ ALL may involve a pluripotential stem cell
because bcr-abl, the molecular counterpart of the Ph chro-
mosome, may be detectable in isolated B cells, T cells,
myeloid cells, and erythroid cells from patients with Ph+
ALL [9]. Both children and adults with Ph+ ALL tend to be
older, present with higher white blood cell count (WBC)
[7,10,11], and may have a higher incidence of central ner-
vous system involvement than patients with Ph– ALL [4].
The bcr-abl oncogene is detected in 2 variant forms—
p190 and p210—by sensitive reverse transcriptase–polymerase
chain reaction (RT-PCR) techniques. In adults with Ph+
ALL, the p190 form is detected in about 50% of patients. In
pediatric patients, p190 is the dominant variant and is
detected in about 90% of patients [2,12]. Generally, there
are no signiﬁcant differences in the biology or response to
chemotherapy in p190+ versus p210+ ALL [13]. However, a
recent report on allogeneic stem cell transplantation (SCT)
for Ph+ ALL suggested that the expression of p190 bcr-abl
after SCT was associated with a signiﬁcantly increased risk
of relapse compared with that of the p210 variant [14].
EXPERIENCE WITH CHEMOTHERAPY
Patients with Ph+ ALL have an extremely poor progno-
sis for long-term survival when treated with chemotherapy
alone. Initial responses to induction chemotherapy may be
comparable to those reported for Ph– ALL, but early
relapses are common. Median disease-free survival (DFS)
for adults treated with chemotherapy alone ranges from 5 to
9 months [8,15,16]. The probability of continuous complete
remission was only 6% after 39 months in a study of
25 patients [17]. In a recent report from M.D. Anderson
Cancer Center (Houston, TX), current results with a more
intensive regimen of cyclophosphamide, vincristine, adri-
amycin, and dexamethasone (hyper-CVAD), were compared
to results achieved before 1992 with either vincristine,
Allogeneic Stem Cell Transplantation for Philadelphia
Chromosome–Positive Acute Lymphoblastic Leukemia
David S. Snyder
Division of Hematology/Bone Marrow Transplantation, City of Hope National Medical Center, Duarte, California
Correspondence and reprint requests: Dr. David S. Snyder, Division of Hematology/Bone Marrow Transplantation, 
City of Hope National Medical Center, 1500 E. Duarte Rd., Duarte, CA 91010 (e-mail: dsnyder@coh.org).
Received August 12, 2000; accepted August 15, 2000
ABSTRACT
The prognosis for adult and pediatric patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic
leukemia (ALL) treated with chemotherapy alone is extremely poor. An overview of the biology and clinical features
of Ph+ ALL is presented in this review. The experience with chemotherapy and autologous stem cell transplantation
(SCT) is summarized. Allogeneic SCT offers a curative option for patients who have an appropriately matched
donor. Variables affecting outcome after allogeneic SCT, including age, stage of disease, source of stem cells,
preparatory regimen, and molecular and cytogenetic details, are analyzed. The City of Hope/Stanford University
experience with fractionated total body irradiation and high-dose etoposide is described, and future directions for
monitoring and treating minimal residual disease are discussed.
KEY WORDS
Acute lymphoblastic leukemia • Philadelphia chromosome • Stem cell transplantation 
Biology of Blood and Marrow Transplantation 6:597-603 (2000)
© 2000 American Society for Blood and Marrow Transplantation ASBMT




adriamycin, and dexamethasone (VAD) or acute myeloid
leukemia (AML)-like protocols. Although the hyper-CVAD
regimen demonstrated an improved response rate and DFS,
there was no improvement in overall survival time, with a
median survival of only 66 weeks [16]. Patients with no
chromosomal abnormalities, including hyperdiploid kary-
otypes, in addition to the Ph+ may have better outcomes
than patients with monosomy 7 or 9p anomalies [6].
The results for pediatric patients with Ph+ ALL treated
with chemotherapy alone are not much better than those
reported for adults. Complete remission induction rates are
either similar to [11] or lower than [10] those reported for
Ph– ALL. However, event-free survival (EFS) is uniformly
inferior in Ph+ ALL versus Ph– ALL. In a Children’s Cancer
Group report of 30 patients with newly diagnosed Ph+ ALL,
EFS at 4 years was 11.3% compared with 73.4% of 1292
Ph– cases [18]. The Berlin-Frankfurt-Munster (BFM) Study
Group reported a probability of EFS at 5 years of 11% for
30 Ph+ children treated after first relapse, compared with
46% for 277 Ph– patients by matched-pair analysis [5].
On a more positive note, the St. Jude group [19] identi-
fied a subset of 10 children who presented with a WBC
≤ 25,000 and who achieved a 4-year EFS rate of 73% ± 19%
compared with 10% ± 7% for 13 patients with >25,000
WBC after treatment with an intensive chemotherapy regi-
men. Recently, it has been reported that good initial
response to steroids is an early predictor of a favorable out-
come for children with ALL. This observation was con-
ﬁrmed for 61 Ph+ patients of a larger group of 4760 patients
enrolled in 2 BFM/Associazione Italiana di Ematologia ed
Oncologia Pediatrica studies. Two thirds of the Ph+ patients
were identified as good prednisone responders, and their
probability of EFS at 4.1 years was 55% compared with
10% for the patients who were poor prednisone responders
[20]. Some of those patients did go on to allogeneic SCT
after initial chemotherapy. Similarly, Arico et al. [21]
reported that patients who were poor responders to gluco-
corticoids and intrathecal methotrexate had an EFS of 0
within 2 years of diagnosis; good responders had a 5-year
EFS of 39% ± 7%.
AUTOLOGOUS SCT
Several groups have reported results of autologous SCT
for patients with Ph+ ALL. Five patients were treated by
autologous SCT while in complete remission (CR) (4 in ﬁrst
CR, 1 in second CR) using a combination of fractionated
total body irradiation (FTBI), high-dose etoposide (VP-16),
and cyclophosphamide (CY) [22]. Of the 5 patients,
4 relapsed, and 1 patient was alive in CR at >47.5 months.
Twenty-five patients treated with autologous SCT were
included in the recent report by Arico et al. [21]. Of the 25
patients, 14 relapsed, 3 died in CR, and 2 developed a sec-
ond malignancy, leaving 6 of 25 in continued CR. In the
report by Dunlop et al. [23], 9 patients underwent autolo-
gous SCT (8 in ﬁrst or second CR, 1 in ﬁrst relapse) using
melphalan with or without TBI. The 3-year probabilities of
relapse and DFS were 65.9% and 25.6%, respectively. In
each of these studies, the relapse rate was high, although a
small percentage of patients were alive in continued CR at 2
to 3 years after SCT.
ALLOGENEIC SCT
Allogeneic SCT has been used for many years as
postinduction therapy to improve DFS for patients with
Ph+ ALL [24,25] and is a curative treatment for a signiﬁcant
number of patients. The experience with allogeneic SCT is
reviewed below and focuses on risk factors such as age,
stage of disease, type of transplantation, conditioning regi-
men, and bcr-abl RT-PCR results.
The results from 6 studies of allogeneic SCT are summa-
rized in Table 1. These reports include patients who were in
various stages of remission after chemotherapy and who
received stem cells from either matched siblings or unrelated
donors. DFS rates ranged from 21.8% to 68.6%, with relapse
rates ranging from 10.8% to 63.4%. Late relapses were seen
in all studies, independent of the type of transplantation. No
consistent risk factors were identiﬁed to predict for relapse or
survival, perhaps because the number of patients in each of
the studies was fairly small. The presence or absence of graft-
versus-host disease was not a signiﬁcant risk factor. In the
City of Hope/Stanford University study [26], the stage of dis-
ease at the time of transplantation was a signiﬁcant predictor
of survival, although this ﬁnding was not conﬁrmed in 2 other
reports [23,27]. Patients who were younger than 30 years had
better outcomes in the study by Kröger et al. [22].
The type of transplantation (allogeneic versus autolo-
gous) did not make a difference in outcome in the study by
Dunlop et al. [23]; however, as discussed previously, the
results for autologous SCT are generally quite poor. The
results for matched unrelated SCT were comparable to those
observed in sibling donor SCT in 2 studies [28,29], but not
in the City of Hope/Stanford University experience [26].
Whether the components of the preparatory regimen
are critical in determining relapse and survival is difﬁcult to
answer in the absence of randomized, comparative trials.
Most transplantation centers have used a combination of
FTBI and CY as the conditioning regimen for SCT. High-
dose VP-16 in combination with FTBI was piloted as an
alternative to FTBI/CY by City of Hope [30]. Investigators
at the City of Hope and at other centers have used VP-16–
containing conditioning regimens for the treatment of a
variety of advanced hematologic malignancies, including
Ph+ ALL [22,31-35].
The City of Hope/Stanford University experience with
high-dose VP-16–containing conditioning regimens for
patients with Ph+ ALL is reviewed below [26,36]. A total of
47 patients with an age range of 3.5 to 56.6 years (median,
29.6 years) received transplants between 1984 and 1998 using
high-dose VP-16 as part of the conditioning regimen. All
except 2 patients received hematopoietic cells in the form of
unmanipulated bone marrow from HLA-matched sibling
donors. One patient received granulocyte colony-stimulating
factor (G-CSF)–primed peripheral blood stem cells from her
HLA-matched sister, and 1 patient received cord blood cells
from a matched sibling. Twenty-three patients underwent
transplantation in ﬁrst CR, and 24 patients were beyond ﬁrst
CR (10 induction failures, 9 in ﬁrst relapse, and 5 in more
advanced conditions). For 22 of the 23 patients in ﬁrst CR,
the preparatory regimen consisted of FTBI (1320 cGy deliv-
ered in 11 fractions over 4 days), followed by VP-16 at
60 mg/kg [30,31] and a combination of FTBI/VP-16/CY in 1
patient [37]. For 13 of 24 patients beyond ﬁrst CR, the regi-
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men was FTBI/VP-16; for the other 11 patients, it was
FTBI/VP-16/CY.
The probability of 5-year DFS for all 47 patients was
50%, and the probability of relapse was 30.0%. There was a
signiﬁcant difference in DFS when patients were divided into
cohorts by date of transplantation. For those patients who
underwent transplantation before 1992, the probability of
DFS was 38% compared with 65% for those who underwent
transplantation after 1992 (P = .03, log-rank test). This differ-
ence may be explained by improvements in supportive care
and in the management of infections with cytomegalovirus
[38] or fungi [39], because there was no signiﬁcant difference
in relapse rates for these 2 groups. For the 23 patients who
underwent transplantation in first CR, the probabilities of
5-year DFS and relapse were 62% and 12%, respectively; for
the 24 patients who underwent transplantation beyond ﬁrst
CR, the probabilities were 38% and 45%, respectively. The
relapse rate is quite low and the DFS rate high, especially for
the ﬁrst-CR patients, compared with other published reports.
The DFS curves for the 2 groups are shown in Figure 1, and
the differences are signiﬁcant by the log-rank test (P = .02).
A group of investigators from Germany [40] described
their results for 10 patients who received transplants for Ph+
ALL from sibling, matched related, or matched unrelated
donors. All patients were conditioned with a regimen of
TBI/CY/VP-16. Only 2 of the 10 patients relapsed. In an
updated report from this group [22], the 3-year DFS rate for
15 patients who received transplants from allogeneic donors
while in ﬁrst CR was 46%, and for all 24 patients (5 autolo-
gous, 13 allogeneic-related, and 6 allogeneic-unrelated), CR
was 38%. We speculate that the inclusion of high-dose VP-16
in the conditioning regimen may be important in explaining
the lower relapse rates observed both in our study and in the
German studies compared with other reports. The results
from Sobecks et al. [35] failed to conﬁrm these observations:
all 4 Ph+ ALL patients in their study of escalating doses of
FTBI plus VP-16 relapsed after SCT, although the number
of patients studied was small.
CHEMOTHERAPY VERSUS SCT
There are no prospective, randomized trials comparing
outcomes for patients with Ph+ ALL treated with chemo-
therapy alone versus chemotherapy followed by some form
of SCT. However, a recent retrospective study of pediatric
patients with Ph+ ALL from Italy is very informative [21].
The investigators analyzed 267 patients of 326 (82%) who
were diagnosed with Ph+ ALL and achieved a ﬁrst CR with
induction chemotherapy. Ages ranged from 0.4 to
19.9 years (median, 8.1 years). Patients were stratiﬁed into
Table 1. Summary of Studies of Allogeneic Stem Cell Transplantation for Ph+ Acute Lymphoblastic Leukemia*
Median Age
Reference n (Range), y Stage Stem Cell Source Conditioning Regimen Outcome
Barrett et al. 67 28 (5-49) BM, matched siblings FTBI/CY + others 2-y DFS 31%
[27] 33 First CR 2-y DFS 38%; relapse 34%
22 > First CR 2-y DFS 41%; relapse 32%
12 IF 2-y DFS 25%; relapse 57%
Dunlop et al. 11 27 (3-35) BM, matched siblings TBI/melphalan + others 3-y DFS 21.8%; relapse 63.4%
[23] 5 First CR 0/5 alive
6 > First CR 2/6 in continued CR
Sierra et al. 18 25 (1.7-51) BM, matched unrelated CY/FTBI 2-y DFS 49%
[28] 7 First CR 6/7 alive; 0/7 relapsed
11 > First CR 3/11 alive; 5/11 relapsed
Marks et al. 15 8.3 (2.7-19.4) BM, matched unrelated CY/FTBI 2-y DFS 37%
[29] 11/15 full match,
4/15 mismatch at 1 or 2 loci
9 First CR 5/9 alive; 3/9 relapsed
6 > First CR 2/6 alive; 3/6 relapsed
Kröger et al. 19 28.5 (2-60) FTBI/VP-16/CY 3-y DFS 38%; 5-y DFS 35%
[22] first CR patients: 3-y DFS 
46%; 5-y DFS 34.5%
13 First CR (10); BM (11), PBSC (2),
> first CR (3) matched related
6 First CR (5); BM, matched unrelated 1/6 relapsed; 3/6 alive†
first PR (1)
Snyder et al. 76 29.6 (3.5-56.6)
[26] 26 First CR BM (24), PBSC (1), FTBI/VP-16 ± CY 2-y DFS 68.6%; relapse 10.8%
CBSC (1), matched siblings (23); other (3)
35 > First CR BM, matched siblings FTBI/VP-16 ± CY 2-y DFS 36.7%; relapse 38.2%
(25); other (10)
15 First CR (4); BM, matched unrelated FTBI/CY (14); 2-y DFS 6.7%; relapse 59.4%
> first CR (11) FTBI/VP-16/CY (1)
*BM indicates bone marrow; FTBI, fractionated total body irradiation; CY, cyclophosphamide; DFS, disease-free survival; CR, complete remis-
sion; IF, induction failure; VP-16, etoposide; PBSC, peripheral blood stem cells; PR, partial remission; CBSC, cord blood stem cells.
†At 2.3, 12.1, and 20.5 months.
3 prognostic groups: best prognosis (WBC of <50,000 and
aged <10 years); intermediate prognosis; and worst prog-
nosis (WBC,  >100,000). The 5-year DFS for these 3
groups were 49% ± 5%, 30% ± 5%, and 20% ± 5% (P <
.001 for the overall comparison). One hundred patients
went on to SCT (25 autologous, 21 matched unrelated, 16
mismatched related, and 38 matched related donor).
Patients in all 3 prognostic groups who were treated with
matched related SCT had a significant survival advantage
over patients treated with chemotherapy alone, with a rela-
tive risk of death or adverse event of 0.3. This advantage
became more apparent with each successive year of follow-
up, implying that SCT provided greater protection against
late relapse than did chemotherapy alone. There was no
such advantage for any other type of SCT. Figure 2 shows
the results for DFS and overall survival for the patients




Figure 1. Probability of disease-free survival for patients treated either in ﬁrst complete remission (CR) or in more advanced stages of disease (> ﬁrst
CR) using VP-16 (etoposide)–containing conditioning regimens at City of Hope/Stanford University. Tick marks indicate censoring. Log-rank P = .02.
Figure 2. Probability of overall and disease-free survival for pediatric patients treated with chemotherapy alone or chemotherapy followed by
matched related stem cell transplantation. (Reprinted with permission from Arico et al [21]. Copyright 2000, Massachusetts Medical Society.)
>1 CR (n = 24)
1 CR (n = 23)
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DETECTION OF MINIMAL RESIDUAL DISEASE
Detection of bcr-abl transcripts by RT-PCR, with the
ability to detect as few as 1 in 105 or 106 cells, is an
extremely sensitive method for monitoring minimal resid-
ual disease after chemotherapy and SCT. Preudhomme et
al. [41] found a good correlation between RT-PCR positiv-
ity and relapse, with a switch to bone marrow positivity by
PCR 4 to 6 months before clinical relapse in all patients
that had achieved remission with chemotherapy with or
without subsequent SCT. It is evident that some patients
may have detectable bcr-abl transcripts by RT-PCR after
SCT, yet have no other evidence of residual or relapsed dis-
ease. Sierra et al. [28] reported that of 9 patients in CR
after matched unrelated donor SCT, 7 were bcr-abl negative
and 2 were positive, despite continued cytogenetic and
hematologic remission (Figure 3).
The type of bcr-abl transcript detected after SCT may be
an important discriminator of risk of relapse [14]. For
patients who had detectable bcr-abl p190 by RT-PCR, the
relative risk of relapse was 11.2 compared with patients who
were bcr-abl negative, whereas the presence of p210 tran-
scripts carried no increased risk. This observation was sup-
ported by the results of Snyder et al. [26], but not by the
data from Kröger et al. [22]. Additional studies are needed
to conﬁrm the validity of this observation.
More recently, quantitative RT-PCR assays have been
used to monitor the dynamics of residual leukemic cells after
treatment with chemotherapy and SCT. These assays allow
investigators to document ﬂuctuations in the number of copies
of bcr-abl transcripts and perhaps guide clinical decision-mak-
ing about the timing of intervention for relapsed disease. Mit-
terbauer et al. [42] followed 16 patients with Ph+ ALL as they
went through their courses of therapy. The number of bcr-abl
transcripts was reduced by 2 to 3 logs after induction chemo-
therapy and by more than 3 logs in 2 patients who underwent
autologous SCT after chemotherapy. Two patients treated
with allogeneic SCT had undetectable bcr-abl transcripts for
7 and 11 months, but they then relapsed, with a >1 log
increase in bcr-abl transcripts before overt relapse.
FUTURE DIRECTIONS
Unfortunately, relapse rates for patients with Ph+ ALL
treated with allogeneic SCT are still quite high, despite inten-
sive conditioning regimens. Graft-versus-leukemia effects are
typically considered weak for ALL in general compared with
those of chronic myelogenous leukemia (CML) or AML [43-
45]. Response rates to treatment with donor leukocyte infu-
sions (DLIs) for relapsed ALL after sibling donor or matched
unrelated donor SCT ranged from 18% to 50% [44,46], with
small numbers of patients studied and very few long-term sur-
vivors. In 1 case report [47], a 12-year-old girl with Ph+ ALL
was treated with 3 rounds of DLI for persistently positive RT-
PCR but no hematologic evidence of relapse. She achieved
PCR negativity and remained in hematologic CR 11 months
after SCT from an HLA-identical sibling.
DLI therapy is not benign: it is associated with a
significant risk of graft-versus-host disease and aplasia. It
may emerge that quantitative RT-PCR will be more reli-
able at predicting which patients are destined to relapse
clinically after SCT and that rising levels of bcr-abl tran-
scripts by this criteria will help guide clinicians in deciding
whether to intervene after SCT.
A novel approach to the treatment of minimal residual
disease after SCT is being developed at City of Hope using
specifically targeted, donor-derived CD8+ T-cell clones.
Figure 3. Cytogenetic and molecular analysis of 9 patients in clinical complete remission after matched unrelated donor stem cell transplantation.
UPN, unique patient number; Pre Tx, before transplantation; m, months; PCR, polymerase chain reaction. (Reprinted with permission from Sierra et al
[28]. Copyright 1997, American Society of Hematology.)
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Preclinical results have been reported targeting CD20+ cells
[48], and work is in progress to develop T-cell clones tar-
geting CD19+ cells. This method may be safer than DLI
and, it is hoped, even more effective in treating early
relapse of Ph+ ALL after SCT. Another innovative approach
that may help reduce the residual tumor burden before
SCT and perhaps prevent relapse after SCT is the use of
tyrosine kinase inhibitors directed against the Bcr-Abl pro-
tein [49,50]. These agents have shown considerable
promise in the treatment of CML [51] and will be tested in
upcoming trials for the treatment of Ph+ ALL.
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